Filing Flows › Comparisons › XTNT vs NPCE
Xtant Medical Holdings vs NeuroPace: XTNT and NPCE compared
Xtant Medical Holdings is the larger company: $23.0M of revenue in its latest quarter (Q2 2026) against $22.8M for NeuroPace (Q2 2026). NeuroPace is growing faster (+17% against -35% a year earlier). NeuroPace is more profitable, with an operating margin of -22.5% against -39.8%.
Where the money goes: XTNT and NPCE
Xtant Medical Holdings (XTNT) · Q2 2026
Xtant Medical Holdings, Q2 2026: revenue $23.0M (-35% year over year), operating margin -39.8%, net loss $9.4M, operating cash flow −$7.3M. The chart follows the revenue to costs, profit and cash.
NeuroPace (NPCE) · Q2 2026
NeuroPace, Q2 2026: revenue $22.8M (+17% year over year), operating margin -22.5%, net loss $6.2M, operating cash flow −$3.9M. The chart follows the revenue to costs, profit and cash.
| Xtant Medical Holdings (XTNT) | NeuroPace (NPCE) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $23.0M | $22.8M |
| Revenue growth, Y/Y | -35% | +17% |
| Operating margin | -39.8% | -22.5% |
| Net earnings | −$9.4M | −$6.2M |
| Net margin | -40.9% | -27.2% |
| Operating cash flow | −$7.3M | −$3.9M |
Where the revenue comes from
Xtant Medical Holdings
- Orthobiologics: $17.4M (75%)
- Spinal Implant: $5.7M (25%)
Questions
Which is bigger, Xtant Medical Holdings or NeuroPace?
Xtant Medical Holdings is the larger company: $23.0M of revenue in its latest quarter (Q2 2026) against $22.8M for NeuroPace (Q2 2026).
Is Xtant Medical Holdings or NeuroPace growing faster?
NeuroPace is growing faster (+17% against -35% a year earlier).
Which is more profitable, Xtant Medical Holdings or NeuroPace?
NeuroPace is more profitable, with an operating margin of -22.5% against -39.8%.
More: Xtant Medical Holdings earnings · how Xtant Medical Holdings makes money · NeuroPace earnings · how NeuroPace makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.